Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

Tomas Kalincik,Sifat Sharmin,Izanne Roos,Mark S Freedman,Harold Atkins,Joachim Burman,Jennifer Massey,Ian Sutton,Barbara Withers,Richard Macdonell,Andrew Grigg,Øivind Torkildsen,Lars Bo,Anne Kristine Lehmann,Eva Kubala Havrdova,Eva Krasulova,Marek Trnený,Tomas Kozak,Anneke van der Walt,Helmut Butzkueven,Pamela McCombe,Olga Skibina,Jeannette Lechner-Scott,Barbara Willekens,Elisabetta Cartechini,Serkan Ozakbas,Raed Alroughani,Jens Kuhle,Francesco Patti,Pierre Duquette,Alessandra Lugaresi,Samia J Khoury,Mark Slee,Recai Turkoglu,Suzanne Hodgkinson,Nevin John,Davide Maimone,Maria Jose Sa,Vincent van Pesch,Oliver Gerlach,Guy Laureys,Liesbeth Van Hijfte,Rana Karabudak,Daniele Spitaleri,Tunde Csepany,Riadh Gouider,Tamara Castillo-Triviño,Bruce Taylor,Basil Sharrack,John A Snowden,Saloua Mrabet,Justin Garber,Jose Luis Sanchez-Menoyo,Eduardo Aguera-Morales,Yolanda Blanco,Abdullah Al-Asmi,Bianca Weinstock-Guttman,Yara Fragoso,Koen de Gans,Allan Kermode

JAMA neurology（2023）

引用 2|浏览21

暂无评分

摘要

In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.

查看译文

关键词

multiple sclerosis,natalizumab,transplant,relapsing-remitting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要